Introduction
Acinetobacter baumannii, a gram-negative, non-fermentative bacterium,
is one of the most important nosocomial pathogens in
hospitals, especially in intensive care units. A. baumannii is an
opportunistic pathogen that causes serious nosocomial outbreaks.
The mortality rate is elevated and the length of hospitalization is
prolonged if drug resistance develops [1,2]. In recent years, multidrug
resistant A. baumannii have been spread worldwide including
Taiwan [3–5]. More recently, the term ‘‘extensively drug
resistant’’ A. baumannii (XDRAB) has been used to characterize
the bacterial isolates resistant to all authorized antibiotics except 2
category of antibiotic e.g. tigecycline and polymyxins [4,6,7].
Given the increasing prevalence of XDRAB infection with high
mortality rate, new antibiotics and are needed to combat this
challenge, and one possible solution is the therapeutic use of
phages [8–13].